27 patents
Utility
Cycloalkyl pyrimidines as ferroportin inhibitors
5 Sep 23
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
Filed: 28 Apr 21
Utility
Histone methyltransferase inhibitors
1 Aug 23
Ming Yu, Zhe Li
Filed: 4 Nov 20
Utility
Tricyclic compounds as histone methyltransferase inhibitors
30 May 23
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease).
Zhe Li, Ming Yu, Qing Xu, Manuel Zancanella
Filed: 13 Aug 18
Utility
Tricyclic compounds as histone methyltransferase inhibitors
21 Feb 23
Ming Yu, Zhe Li, Qing Xu, Calvin Yee, Lina Setti, Hing Sham
Filed: 13 Aug 18
Utility
Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
31 Jan 23
Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
Filed: 7 Feb 22
Utility
Modulators of hemoglobin
10 Jan 23
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
Zhe Li
Filed: 4 May 20
Utility
Compounds and uses thereof for the modulation of hemoglobin
20 Dec 22
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 21 Sep 20
Utility
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
27 Sep 22
Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N.
Zhe Li, Stephan D. Parent, Travis Houston
Filed: 8 Jul 20
Utility
Ferroportin inhibitors and methods of use
29 Mar 22
Zhe Li, Qing Xu, Brian Walter Metcalf, Calvin Wesley Yee, Peter Michael Rademacher, Carsten Alt
Filed: 12 Dec 19
Utility
Histone methyltransferase inhibitors
22 Feb 22
The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease.
Ming Yu, Zhe Li, Lina Q. Setti
Filed: 15 Feb 17
Utility
Compounds and uses thereof for the modulation of hemoglobin
1 Feb 22
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 18 Mar 19
Utility
Azaindole compounds as histone methyltransferase inhibitors
7 Sep 21
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease).
Chul Yu, Ming Yu, Manuel Zancanella, Zhe Li
Filed: 7 Jun 18
Utility
Compounds and uses thereof for the modulation of hemoglobin
6 Jul 21
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Qing Xu, Zhe Li, Stephen L. Gwaltney, II
Filed: 9 Nov 18
Utility
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
1 Jun 21
Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha
Filed: 2 Dec 16
Utility
Modulators of hemoglobin
25 May 21
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
Brian W. Metcalf, Zhe Li, Qing Xu, Kobina N. Dufu, James Partridge, Hing Sham, Ming Yu
Filed: 30 Sep 19
Utility
Compounds and uses thereof for the modulation of hemoglobin
7 Dec 20
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Qing Xu, Zhe Li
Filed: 11 Apr 19
Utility
Histone methyltransferase inhibitors
9 Nov 20
Ming Yu, Zhe Li
Filed: 20 Dec 17
Utility
Compounds and uses thereof for the modulation of hemoglobin
9 Nov 20
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
Filed: 29 Mar 18
Utility
Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
2 Nov 20
Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Brian Metcalf, Chihyuan Chuang
Filed: 22 Jul 19
Utility
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
19 Oct 20
Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Brian Metcalf, Chihyuan Chuang
Filed: 24 Jun 18